Merck, American Diabetes Association partner to educate adults with diabetes
The collaboration will help people with Type 1 or Type 2 diabetes to talk to their health care professional (HCP) about these diseases. Merck medical director Mel Kohn
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).